<DOC>
	<DOCNO>NCT00043004</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread block blood flow . Others find tumor cell help kill carry tumor-killing substance . Radiofrequency ablation use high-frequency electric current kill tumor cell . It yet know chemotherapy effective without radiofrequency ablation treat liver metastasis . PURPOSE : This randomized phase II trial study combination chemotherapy , bevacizumab , radiofrequency ablation see well work compare combination chemotherapy bevacizumab alone treat unresectable liver metastases patient colorectal cancer .</brief_summary>
	<brief_title>Chemotherapy Bevacizumab With Without Radiofrequency Ablation Treating Unresectable Liver Metastases Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare 30-month overall survival rate patient unresectable liver metastasis secondary colorectal adenocarcinoma treat chemotherapy bevacizumab without radiofrequency interstitial ablation . Secondary - Compare overall survival patient treat regimen . - Compare quality life patient treat regimen . - Determine health economics associate study . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord treatment center , prior adjuvant chemotherapy primary cancer ( yes v ) , prior chemotherapy liver metastasis ( yes v ) , route randomization ( surgery v surgery ) . Patients randomize 1 2 treatment arm . - Arm I : Within 4 week randomization , patient undergo radiofrequency interstitial ablation ( RFA ) without additional resection resectable lesion . Within 8 week RFA , patient receive chemotherapy bevacizumab . - Arm II : Within 4 week randomization , patient receive chemotherapy bevacizumab . In arm , treatment continue absence disease progression unacceptable toxicity . Patients arm receive one follow chemotherapy bevacizumab regimen determine participate center : - Regimen A : Patients receive oxaliplatin IV 2 hour day 1 week 1 , 3 , 5 leucovorin calcium IV 2 hour follow fluorouracil IV continuously 24 hour day 1 week 1-6 bevacizumab IV 30-90 minute day 1 2 , 15 16 , 29 30 . Treatment repeat every 7 week 4 course . - Regimen B : Patients receive oxaliplatin IV leucovorin calcium IV 2 hour day 1 follow fluorouracil IV continuously 46 hour bevacizumab IV 30-90 minute day 1 3 . Treatment repeat every 15 day 12 course . - Regimen C : Patients receive oxaliplatin IV 2 hour day 1 leucovorin calcium IV 2 hour follow fluorouracil IV continuously 22 hour day 1 2 bevacizumab IV 30-90 minute day 1 3 . Treatment repeat every 15 day 12 course . Quality life assess baseline , within 1 week completion RFA ( arm I ) , within 1 week start chemotherapy ( arm I ) , week 6 , 12 , 18 , 24 chemotherapy , every 3 month 2 year treatment , every 6 month thereafter . After completion study treatment , patient follow every 3 month 2Â½ year every 6 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 152 patient ( 71 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Unresectable liver metastasis secondary colorectal adenocarcinoma , include : Metastases radically resect due size , location , number deposit Metastases invade right leave branch hepatic artery portal vein Metastases extend 3 main hepatic vein No detectable extrahepatic disease Fewer 10 metastatic deposit liver Total metastatic involvement liver 50 % Adequate treatment metastatic lesion deem possible either radiofrequency interstitial ablation ( RFA ) alone combination resection resectable lesion RFA remain unresectable lesion Maximum diameter 4 cm lesion treat RFA No maximum diameter lesion resect long negative resection margin obtainable If synchronous liver metastasis , must undergo prior resection primary tumor PATIENT CHARACTERISTICS : Age 18 80 Performance status WHO 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 No bleed disorder coagulopathy need fulldose anticoagulation Hepatic Bilirubin less 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN Renal Creatinine less 2 time ULN Protein &lt; 0.5 g/24 hr urine collection proteinuria positive dipstick Cardiovascular No uncontrolled congestive heart failure No uncontrolled angina pectoris No uncontrolled hypertension No uncontrolled arrhythmia No myocardial infarction within past 12 month No cerebrovascular accident transient ischemic attack within past 6 month Other Not pregnant nursing Fertile patient must use effective contraception No great grade 1 peripheral neuropathy No significant neurologic psychiatric disorder No active infection No contraindication use fluorouracil , leucovorin calcium , oxaliplatin , bevacizumab No malignancy within past 10 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy except metastatic disease confine liver Prior fluorouracil , leucovorin calcium , oxaliplatin allow administer least 3 course ( 2 week ) longer 3 month least stabilization disease achieve Prior adjuvant chemotherapy primary cancer allow except patient receive oxaliplatin diagnose metastatic disease within 12 month completion adjuvant treatment Endocrine therapy Not specify Radiotherapy Not specify Surgery More 28 day since major surgery open biopsy past 28 day More 28 day since significant traumatic injury Other No concurrent investigational treatment No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>